Order Article Reprints

Merlano MC, Paccagnella M, Denaro N, Abbona A, Galizia D, Sangiolo D, Gammaitoni L, Fiorino E, Minei S, Bossi P, et al. Baseline Values of Circulating IL-6 and TGF-β Might Identify Patients with HNSCC Who Do Not Benefit from Nivolumab Treatment. Cancers. 2023; 15(21):5257. https://doi.org/10.3390/cancers15215257

Merlano, Marco Carlo, Matteo Paccagnella, Nerina Denaro, Andrea Abbona, Danilo Galizia, Dario Sangiolo, Loretta Gammaitoni, Erika Fiorino, Silvia Minei, Paolo Bossi, and et al. 2023. "Baseline Values of Circulating IL-6 and TGF-β Might Identify Patients with HNSCC Who Do Not Benefit from Nivolumab Treatment" Cancers 15, no. 21: 5257. https://doi.org/10.3390/cancers15215257

Merlano, M. C., Paccagnella, M., Denaro, N., Abbona, A., Galizia, D., Sangiolo, D., Gammaitoni, L., Fiorino, E., Minei, S., Bossi, P., Licitra, L., & Garrone, O. (2023). Baseline Values of Circulating IL-6 and TGF-β Might Identify Patients with HNSCC Who Do Not Benefit from Nivolumab Treatment. Cancers, 15(21), 5257. https://doi.org/10.3390/cancers15215257